Abstract Hyperinsulinemia resulting from peripheral insulin resistance has been demonstrated both in spontaneously hypertensive rats (SHR) and in humans with essential hypertension. A new class of antidiabetic drugs, thiazolidinediones, which can improve insulin resistance, may be able to lower not only blood glucose levels but also blood pressure. The present study was therefore designed to clarify the proportion of SHR that are glucose intolerant and to observe the effect on blood pressure of CS-045 (troglitazone) administered at 70 mg/kg per day for 2 weeks to male SHR (n=13). Among 67 male 8-week-old SHR, 74.6% were glucose intolerant and hyperinsulinemic. Systolic blood pressure did not correlate with plasma glucose or insulin levels before or after glucose loading. Treatment with CS-045 improved insulin resistance, as evidenced by a smaller area
I t is well known that patients with obesity or noninsulin-dependent diabetes mellitus (NIDDM) often have associated hypertension. On the other hand, essential hypertension recently has been shown to be often associated with obesity, glucose intolerance, or NIDDM. 12 In fact, patients with essential hypertension, even if they are not obese, have been demonstrated to be insulin resistant by the euglycemic hyperinsulinemic clamp technique. 3 In this sense, hypertension, NIDDM, and obesity share a common pathophysiological characteristic of insulin resistance. Hyperinsulinemia as a result of insulin resistance in peripheral tissue, mainly skeletal muscle, may enhance sodium reabsorption from the kidneys 4 and/or increase sympathetic nervous activity, 5 causing an increase in blood pressure.
Sulfonylurea, now used widely as a hypoglycemic agent for patients with NIDDM, appears to stimulate pancreatic insulin secretion. Thiazolidinediones are a new class of antidiabetic compounds being developed for the treatment of NIDDM patients. 6 These drugs have been reported to improve peripheral tissue insulin sensitivity and to lower the levels of plasma glucose and insulin in experimental diabetes models and NIDDM patients. 79 If hyperinsulinemia causes high blood pressure in hypertensive rodent models as well as in patients with essential hypertension, such drugs may ameliorate not only the From the Fourth Department of Medicine, Saitama (Japan) Medical School.
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under the curve of plasma glucose and insulin levels in response to glucose loading. However, systolic blood pressure was not altered. When the data were reanalyzed according to the presence or absence of glucose intolerance before the treatment, blood pressure in the treated group was the same as in controls despite significant improvement in steady-state plasma glucose levels. These results suggest that hyperinsulinemia and/or insulin resistance may not be involved in the development or maintenance of hypertension in SHR, which is in contrast to models of hypertension such as obese Zucker rats or fructose-fed rats. Key Words • insulin resistance • rats, inbred SHR • thiazoles • blood pressure underlying metabolic derangements but also hypertension. In fact, drugs such as ciglitazone 10 and CS-045 (troglitazone) 11 have been reported to decrease blood pressure in the obese Zucker rat. The present study was therefore designed to test whether or not insulin resistance and hyperinsulinemia contribute to hypertension in spontaneously hypertensive rats (SHR, a model of human essential hypertension), which also have been reported to have glucose intolerance, hyperinsulinemia, and hence, insulin resistance.
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Methods
Male SHR (n=67) and Wistar rats (n=5) aged 8 weeks obtained from Charles River Japan were housed with free access to food and tap water. Systolic blood pressure was measured by a tail-cuff method. Background data are shown in Table 1 . Blood samples were obtained from a jugular vein before and 60 and 120 minutes after glucose loading (2 g/kg IP) to determine plasma glucose and insulin concentrations after an overnight fast.
In a separate group (n=13) of male SHR aged 10 weeks, CS-045 (Sankyo Co, Ltd) was administered orally by gavage at 70 mg/kg for 2 weeks. Controls (n=12) received only 2.5 mL/kg vehicle (polyethylene glycol to glycerol to water, 194:12:20 wt/wt). Before and after the 2 weeks of treatment, systolic blood pressure and levels of plasma glucose and insulin before and after glucose loading were determined (see Table  2 ). In addition, steady-state plasma glucose (SSPG) levels were determined according to the method of Mondon and Reaven. 13 Briefly, rats anesthetized by pentobarbital received a continuous infusion (1 mL/h) of epinephine (0.08 Mg/kg per minute), propranolol (1.7 fig/kg per minute), glucose (8 mg/kg per minute), and insulin (1.25 mU/kg per minute) though a catheter inserted into a femoral vein. Two hours after the start of infusion, blood samples were drawn from the tail vein for measurement of SSPG levels.
Plasma glucose levels were determined by a standard glucose oxidase method and insulin levels by a radioimmunoassay using rat insulin as standard.
All data are expressed as mean±SEM. Repeated-measures ANOVA, ANOVA followed by Duncan's multiple range test, or Student's / test was used for comparison of data between different groups. Correlations were measured as Pearson's correlation coefficients. Differences were considered significant at a value of / ) <.05.
Results
Among the 67 SHR, 50 (74.6%) demonstrated a plasma glucose response to intraperitoneal glucose loading higher than the mean+2 SD for age-matched Wistar rats (5.66 mmol/L at 60 minutes and 7.97 mmol/L at 120 minutes). As shown in Fig 1, SHR with higher plasma glucose levels demonstrated significantly higher plasma insulin levels. Regression analysis revealed no significant correlation between systolic blood pressure and fasting or postloading plasma glucose and insulin levels. Systolic blood pressure was not correlated with the area under the curve for glucose and insulin levels, as illustrated in Fig 2. Treatment with CS-045 had no effect on body weight gain (296±2.7 versus 290.3±3.0 g in controls). Fig 3 illustrates plasma glucose and insulin levels before and after glucose loading. In the group treated with CS-045, the plasma glucose and insulin levels were significantly lower than in controls. As a result, the area under the curve for glucose and insulin levels was significantly lower in the treated group than in the controls In the infusion study, SSPG tended to be lower in the CS-045 group in comparison to controls, but the difference did not reach significance (Fig 4A) . Since this might have been due to heterogeneity of glucose tolerance in SHR as described above, we reanalyzed the data according to the presence or absence of glucose intolerance before the treatment. Six rats from each of the control and treated groups had plasma glucose levels higher than the mean+2 SD for normal Wistar rats described above. In these rats, SSPG in the treated group was significantly lower than that in the controls, as shown in Fig  4B. However, systolic blood pressure was not lowered by CS-045 administration as a whole or in the subgroup demonstrating higher plasma glucose levels (Fig 4) .
Discussion
The present study clearly demonstrated glucose intolerance associated with hyperinsulinemia, a characteristic feature of insulin resistance, in SHR in comparison to control Wistar rats. This is consistent with the previous studies by Yamori et al 12 Reaven. 13 However, it should be noted that there is a great heterogeneity of glucose metabolism in SHR; that is, not all SHR are glucose intolerant and hyperinsulin- emic, thus calling into question whether or not hyperinsulinemia is in fact involved in the pathogenesis of hypertension in SHR.
To clarify this point, we attempted to improve insulin resistance by CS-045 administration and to observe any change in blood pressure. As evidenced by a lower response and area under the curve of plasma glucose and insulin levels after glucose loading, CS-045 treatment improved insulin resistance. This was supported by the observation that SSPG tended to decrease and was significantly diminished in the group with impaired glucose tolerance before treatment. However, systolic blood pressure was not lowered by the treatment with CS-045. This is in contrast to previous reports in which thiazolidinediones such as ciglitazone and CS-045 lowered blood pressure in male obese Zucker rats.
10
- 11 In both studies, the drugs were administered for 4 to 8 weeks. The doses of CS-045 administered were about 15 and 67 mg/kg per day, the latter tending to lower blood pressure as early as 1 week after the start of treatment and producing a significant decrease in blood pressure after 6 weeks that was associated with marked natriuresis despite a lack of any difference in body weight. In the present study, the dose used was almost the same as that in the former study, although the 2-week treatment period was shorter than the 8-week period in the former study. However, insulin resistance appeared to be improved by CS-045 treatment. Thus, the discrepancy in the blood pressure response between our study and the previous one may be attributed to the difference in the strains that were used. The obese Zucker fatty rat (fa/fa) is a well-documented animal model of insulin resistance characterized by hyperinsulinemia, obesity, hyperlipidemia, and glucose intolerance in association with mild hypertension. 15 The peripheral insulin resistance observed in these animals results from an impairment of insulin-stimulated glucose uptake into skeletal muscle, the major site of insulin-mediated glucose disposal. 16 Recent studies have demonstrated that the major defect may be a failure of translocation of glucose transporter (GLUT) 4 to the plasma membrane, 17 although gene expression of GLUT 4 and its synthesis in adipocytes may be augmented. 18 The other case in which insulin may be involved in the pathogenesis of hypertension may be that in fructose-fed rats, in which somatostatin inhibition of insulin secretion has been reported to decrease blood pressure. 19 This is the case in humans if they are obese and hyperinsulinemic. 20 Very recently, CS-045 administration to fructose-fed rats for 3 weeks was reported to decrease fructoseinduced hypertension from 130±5 to 104±6 mm Hg. 21 In SHR, however, hyperinsulinemia and/or insulin resistance may not be essential for maintenance of high blood pressure, as demonstrated in the present study. Although plasma insulin levels at fasting or after glucose loading in SHR treated with CS-045 was significantly lower than control levels in normal Wistar rats, glucose tolerance or SSPG was not completely normalized, indicating the possibility that there may be a theshold effect of insulin resistance on the regulation in blood pressure.
SHR are very homogeneous in terms of blood pressure. However, they are very often heterogeneous with regard to glucose metabolism even if obtained from a single supplier. Furthermore, wide differences from one colony to another may be evident. Therefore, care must be exercised in using SHR for research in the field of hypertension and insulin resistance.
